Home Forums *News Top Industry News August 19 – 25

Top Industry News August 19 – 25

Home Forums *News Top Industry News August 19 – 25

    • Lauren Feldman

      VOX (August 25, 2023) AI-discovered drugs will be for sale sooner than you think

      It takes forever to get drugs on the market. AI could help speed up the process.


      Harvard John A. Paulson School of Engineering and Applied Sciences (August 24, 2023) Adding immunity to human kidney-on-a-chip advances cancer drug testing

      An immune-infiltrated human kidney organoid-on-chip model enables assessment of kidney toxicities to immunotherapeutic T cell bispecific antibody drugs with high resolution.


      The Human Society of the United States (August 24, 2023) Alleged monkey conspiracy at Inotiv highlights need to end animal testing

      The hurt and harm of animal testing can extend beyond what happens in laboratories, as a new scandal concerning one major animal testing company’s acquisition of monkeys shows. The U.S. Securities and Exchange Commission is investigating whether Inotiv and several of its subsidiaries violated the U.S. Foreign Corrupt Practices Act in efforts to source monkeys from Asia for use in their animal testing facilities and to sell to other laboratories. The Wall Street Journal recently reported that Cambodian officials were allegedly paid to hand out permits stating that wild long-tailed macaques (captured in national parks and protected wild habitats) were bred in captivity. According to prosecutors, this alleged criminal conspiracy went on for about four years.


      News Medical & Life Sciences (August 23, 2023) New kidney tissue model could help assess safety of immunotherapy drugs

      A growing repertoire of cell and molecule-based immunotherapies is offering patients with indomitable cancers new hope by mobilizing their immune systems against tumor cells. An emerging class of such immunotherapeutics, known as T cell bispecific antibodies (TCBs), are of growing importance with several TCBs that the U.S. Food and Drug Administration (FDA) approved for the treatment of leukemias, lymphomas, and myelomas. These antibody drugs label tumor cells with one of their ends, and attract immune cells with another end to coerce them into tumor cell killing.


      BioSpace (August 23, 2023) Curi Bio Awarded Over $4.4M in NIH Grants to Advance Translational Science

      Curi Bio, the industry leader in developing human stem cell-based platforms for drug discovery, proudly announces two recent SBIR grants worth $4.4 million from the National Institutes of Health (NIH) to support its pioneering work on implementing human models to advance discovery of the next generation of medicines. The first project will support expansion of Curi’s cutting-edge in vitro human muscle platform by developing mouse model engineered muscle tissues (EMTs) to bridge the inconsistencies between animal and human data. The second initiative will deliver a novel 3D neuromuscular junction used for disease modeling and potency assays for pharmaceuticals and cosmetics. These grants, the first of their kind received by Curi Bio from the National Center for Advancing Translational Sciences (NCATS), demonstrate the impact that the company’s innovative 3D tissue platforms have made in developing new medicines. These latest awards bring the total non-dilutive funding that Curi Bio has received from the NIH to over $12 million.


      Scoop Politics (August 22, 2023) A Step Forward In Openness In Animal Research And Teaching But More Progress Needed

      New Zealand’s Ministry for Primary Industries (MPI) released 2021 statistics for the use of animals in research, testing and teaching in May. Australian & New Zealand Council for the Care of Animals in Research and Teaching (ANZCCART) NZ commends the publication of the annual statistics as a significant step to ensure open reporting of animal use in research and teaching in New Zealand.


      Forbes (Aug 22, 2023) Induced Pluripotent Stem Cells For Age-Related Macular Degeneration

      Age-related macular degeneration is a progressive eye disorder that leads to severe vision loss in adults over 50. It is caused by damage to the macula, a small area of the retina responsible for sharp central vision, and retinal pigment epithelium cells responsible for nourishing the retina. Age-related macular degeneration affects the middle part of the vision, where detailed activities such as reading and driving are the most important. The disease has no cure, but novel interventions can slow or reverse its progression. One such intervention is stem cell therapy. More specifically, induced pluripotent stem cells (iPSCs) show great promise as a treatment for age-related macular degeneration, as revealed by recent research published in the New England Journal of Medicine.


      Medicines for Malarial Venture (August 22, 2023) New predictive models to support optimal antimalarial use now openly available

      For the first time and after several years of collaboration between MMV, Certara and Monash University, predictive models have been made available for 18 major marketed antimalarials and two in-development compounds. They have been shared, together with an accompanying strategy, for free use by the scientific community. Each model predicts how the body interacts with a specific drug. This helps researchers to optimize the use of currently available antimalarials and better navigate the complexities of drug development thereby supporting the development of safer, more effective, and targeted antimalarial treatments.


      News Medical & Life Sciences (August 21, 2023) Unleashing the Power of Microfluidic Picodroplets

      Interview conducted at SLAS EU 2023 in Brussels, Belgium, with Richard Hammond, Chief Technical Officer at Sphere Fluidics, about Sphere Fluidics’ microfluidic picodroplet technology and more.


      Biopharma Dive (August 21, 2023) Genesis raises $200 million for AI drug discovery research

      AI drug discovery startup Genesis Therapeutics has raised $200 million to push its first drug candidates into clinical testing, announcing Monday a Series B funding round. The financing, which was led by Andreessen Horowitz as well as an unnamed life sciences investor, brings Genesis’ total capital raised to over $280 million. Genesis plans to use the money to advance its pipeline of “AI-enabled” drug programs, and to expand its research in new directions.


      Magicvalley.com (August 18, 2023) Stem Cells Might Someday Create New Tooth Enamel or ‘Living Fillings’ Damaged teeth could one day be repaired with “living fillings” created from stem cells, a new study reports. In the lab, researchers induced stem cells to form small, multicellular mini-organs that secrete the proteins that form tooth enamel, according to a report published Aug. 14 in the journal Developmental Cell.

Viewing 0 reply threads
  • You must be logged in to reply to this topic.